We have read with interest the letter by Delafosse *et al.* describing a cohort of patients with end-stage renal disease with coronavirus disease 2019 (COVID-19) pneumonia undergoing early treatment with glucocorticoids.

Glucocorticoids for the management of COVID-19 are not routinely recommended[@bib1]; however, considering the inflammatory syndrome contributing to the pathogenesis of acute respiratory distress syndrome during the cytokine phase of the disease, glucocorticoids may have a rationale, whether or not in association with drugs targeting cytokines. Data regarding treatment with steroids in the general population are contradictory; the key aspect appears to be the timing of the administration, which is potentially harmful during the viremic phase.[@bib2]

Our experience in hemodialysis patients with established acute respiratory distress syndrome treated with dexamethasone is negative: 28% died and stabilization of the PaO2/FIO2 was recorded only in 22%.[@bib3] Similar mortality rates have been recorded in kidney transplant patients with acute respiratory distress syndrome treated with dexamethasone with or without tocilizumab (36% and 33%, respectively).[@bib4]

Delafosse *et al.* focused on a cohort of 9 patients with end-stage renal disease; 7 were on hemodialysis. An improvement of the respiratory changes has been observed in 7 of 9 after glucocorticoids; of note, the average oxygen requirement of this population was low (3 L/min). COVID-19 in hemodialysis patients may range from asymptomatic to life-threatening cases[@bib3]; these findings should be therefore interpreted cautiously because of the small sample size and the lack of control group.

In conclusion, the role of glucocorticoids in patients with end-stage renal disease and COVID-19 is debated; early commencement might be a potential strategy although confirmation in larger cohorts is required.
